乌帕替尼治疗顽固性肥厚性扁平苔藓 - Suppr

Suppr

超能文献

Treatment of recalcitrant hypertrophic lichen planus with upadacitinib.

作者信息

Schundler Sabrina F, Noot Christiaan H, Frost Zachary, Clarke Jennie, Hopkins Zachary H

机构信息

Rush Medical College, Chicago, Illinois.

Department of Dermatology, University of Utah Spencer F. Eccles School of Medicine, Salt Lake City, Utah.

出版信息

JAAD Case Rep. 2025 Mar 12;59:78-80. doi: 10.1016/j.jdcr.2025.02.029. eCollection 2025 May.

DOI:10.1016/j.jdcr.2025.02.029

PMID:40276729

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12018683/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59b7/12018683/e372aca1ffe3/gr1.jpg

相似文献

Treatment of recalcitrant hypertrophic lichen planus with upadacitinib.

JAAD Case Rep. 2025 Mar 12;59:78-80. doi: 10.1016/j.jdcr.2025.02.029. eCollection 2025 May.

JAK inhibitors in lichen planus: a review of pathogenesis and treatments.

J Dermatolog Treat. 2022 Dec;33(8):3098-3103. doi: 10.1080/09546634.2022.2116926. Epub 2022 Aug 29.

Hypertrophic Lichen Planus and Hypertrophic Skin Lesions Associated with Histological Lichenoid Infiltrate: A Case Report and Literature Review.

Dermatopathology (Basel). 2025 Feb 25;12(1):8. doi: 10.3390/dermatopathology12010008.

PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report.

Drugs R D. 2024 Jun;24(2):353-357. doi: 10.1007/s40268-024-00461-x. Epub 2024 Jun 15.

Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma.

SAGE Open Med Case Rep. 2023 Nov 16;11:2050313X231213144. doi: 10.1177/2050313X231213144. eCollection 2023.

Case report: Hypertrophic lichen planus initially misdiagnosed as squamous cell carcinoma.

Front Med (Lausanne). 2024 May 15;11:1342501. doi: 10.3389/fmed.2024.1342501. eCollection 2024.

Successful Treatment of Lichen Planus With Oral Upadacitinib.

J Drugs Dermatol. 2023 Oct 1;22(10):1058-1060. doi: 10.36849/JDD.7272.

Hypertrophic lichen planus mimicking squamous cell carcinoma: The importance of clinicopathologic correlation.

JAAD Case Rep. 2017 Mar 21;3(2):151-154. doi: 10.1016/j.jdcr.2017.01.020. eCollection 2017 Mar.

Hypertrophic Lichen Planus with Histological Features of Squamous Cell Carcinoma Associated with Immune Checkpoint Blockade Therapy.

Oncologist. 2020 May;25(5):366-368. doi: 10.1634/theoncologist.2019-0796. Epub 2020 Feb 19.

Therapy resistant hypertrophic lichen planus and its response to oral tofacitinib with a priori tissue cytokine expression: a real-world hospital-based study.

Arch Dermatol Res. 2025 Mar 17;317(1):590. doi: 10.1007/s00403-025-04088-z.

本文引用的文献

Oral tofacitinib effectively treating eruptive and hypertrophic cutaneous lichen planus.

JAAD Case Rep. 2023 Apr 26;37:16-20. doi: 10.1016/j.jdcr.2023.04.017. eCollection 2023 Jul.

Hypertrophic Lichen Planus: An Up-to-Date Review and Differential Diagnosis.

Arch Pathol Lab Med. 2024 Jun 1;148(6):659-665. doi: 10.5858/arpa.2022-0515-RA.

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review.

J Cutan Med Surg. 2023 May-Jun;27(3):271-276. doi: 10.1177/12034754231156100. Epub 2023 Feb 23.

JAK inhibitors in lichen planus: a review of pathogenesis and treatments.

J Dermatolog Treat. 2022 Dec;33(8):3098-3103. doi: 10.1080/09546634.2022.2116926. Epub 2022 Aug 29.

Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study.

J Invest Dermatol. 2022 Aug;142(8):2109-2116.e4. doi: 10.1016/j.jid.2022.01.015. Epub 2022 Feb 5.

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Treatment of recalcitrant hypertrophic lichen planus with upadacitinib.

作者信息

Schundler Sabrina F, Noot Christiaan H, Frost Zachary, Clarke Jennie, Hopkins Zachary H

机构信息

Rush Medical College, Chicago, Illinois.

Department of Dermatology, University of Utah Spencer F. Eccles School of Medicine, Salt Lake City, Utah.

出版信息

JAAD Case Rep. 2025 Mar 12;59:78-80. doi: 10.1016/j.jdcr.2025.02.029. eCollection 2025 May.

DOI:10.1016/j.jdcr.2025.02.029

PMID:40276729

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12018683/

Abstract

摘要

相似文献

Treatment of recalcitrant hypertrophic lichen planus with upadacitinib.

JAAD Case Rep. 2025 Mar 12;59:78-80. doi: 10.1016/j.jdcr.2025.02.029. eCollection 2025 May.

JAK inhibitors in lichen planus: a review of pathogenesis and treatments.

J Dermatolog Treat. 2022 Dec;33(8):3098-3103. doi: 10.1080/09546634.2022.2116926. Epub 2022 Aug 29.

Hypertrophic Lichen Planus and Hypertrophic Skin Lesions Associated with Histological Lichenoid Infiltrate: A Case Report and Literature Review.

Dermatopathology (Basel). 2025 Feb 25;12(1):8. doi: 10.3390/dermatopathology12010008.

PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report.

Drugs R D. 2024 Jun;24(2):353-357. doi: 10.1007/s40268-024-00461-x. Epub 2024 Jun 15.

Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma.

SAGE Open Med Case Rep. 2023 Nov 16;11:2050313X231213144. doi: 10.1177/2050313X231213144. eCollection 2023.

Case report: Hypertrophic lichen planus initially misdiagnosed as squamous cell carcinoma.

Front Med (Lausanne). 2024 May 15;11:1342501. doi: 10.3389/fmed.2024.1342501. eCollection 2024.

Successful Treatment of Lichen Planus With Oral Upadacitinib.

J Drugs Dermatol. 2023 Oct 1;22(10):1058-1060. doi: 10.36849/JDD.7272.

Hypertrophic lichen planus mimicking squamous cell carcinoma: The importance of clinicopathologic correlation.

JAAD Case Rep. 2017 Mar 21;3(2):151-154. doi: 10.1016/j.jdcr.2017.01.020. eCollection 2017 Mar.

Hypertrophic Lichen Planus with Histological Features of Squamous Cell Carcinoma Associated with Immune Checkpoint Blockade Therapy.

Oncologist. 2020 May;25(5):366-368. doi: 10.1634/theoncologist.2019-0796. Epub 2020 Feb 19.

Therapy resistant hypertrophic lichen planus and its response to oral tofacitinib with a priori tissue cytokine expression: a real-world hospital-based study.

Arch Dermatol Res. 2025 Mar 17;317(1):590. doi: 10.1007/s00403-025-04088-z.

本文引用的文献

Oral tofacitinib effectively treating eruptive and hypertrophic cutaneous lichen planus.

JAAD Case Rep. 2023 Apr 26;37:16-20. doi: 10.1016/j.jdcr.2023.04.017. eCollection 2023 Jul.

Hypertrophic Lichen Planus: An Up-to-Date Review and Differential Diagnosis.

Arch Pathol Lab Med. 2024 Jun 1;148(6):659-665. doi: 10.5858/arpa.2022-0515-RA.

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review.

J Cutan Med Surg. 2023 May-Jun;27(3):271-276. doi: 10.1177/12034754231156100. Epub 2023 Feb 23.

JAK inhibitors in lichen planus: a review of pathogenesis and treatments.

J Dermatolog Treat. 2022 Dec;33(8):3098-3103. doi: 10.1080/09546634.2022.2116926. Epub 2022 Aug 29.

Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study.

J Invest Dermatol. 2022 Aug;142(8):2109-2116.e4. doi: 10.1016/j.jid.2022.01.015. Epub 2022 Feb 5.

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.